DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Di Nicolantonio F. et al.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
J Clin Oncol 2008; 26: 5705-5712
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.